TGFB2

Across TCGA pan-cancer cohorts, TGFB2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TGFB2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TGFB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGFB2 expression acts as an unfavorable survival marker.

COAD, HNSC, and PRAD are the cancer types where TGFB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.056	0.783	<.001	12	view →
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TGFB2–COAD (OS)

Open the COAD breakdown →